Bioengineered active ingredients

BASF, Boehringer Ingelheim, Pfizer, Merck Group and Novartis are among the companies active in this field. The data lists 48 companies overall, spanning pharmaceutical and personal-care activity. A concrete cosmetics example is BASF's collaboration with Bota Biosciences on SkinNexus Collag3n, a recombinant collagen III fragment launched in July 2026.

Five startups are listed, including Plantibodies, Novelty Nobility and Citryll B.V. Plantibodies develops plant-based biologics, while Novelty Nobility and Citryll focus on antibody-based therapeutics. These examples illustrate how startup activity ranges from plant expression systems to recombinant antibody approaches; the available profiles do not establish a comparative ranking.

The Chinese Academy of Sciences CAS, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION and Medical Foundation are prominent research organizations in the data. The Chinese Academy of Sciences CAS studies microbial conversion of phytosterols into steroidal API precursors, including the EchA19 enzyme. Patent activity at the other organizations includes recombinant protein and peptide compositions.

The data records 4 funding rounds totaling $1,789,581,500 and $10,518,271 in grants across 12 awards since 2020. The round total includes Amgen manufacturing expansions as well as financing for companies such as Citryll B.V. These figures indicate substantial recorded investment, but include events associated with pharmaceutical manufacturing rather than only ingredient-focused startups.

Medical Foundation and PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION lead the listed patent holders with 9 patents each. There were 331 patents in the 24-month window, while patent activity declined 28.5% against the preceding 12-month period. Patent activity is therefore contracting in the measured comparison, despite continued filings across recombinant and other production approaches.

Recent developments include SkinNexus Collag3n, launched by BASF and Bota Biosciences in July 2026, and research on enzyme-enabled modification of glycyrrhetinic acid published that month. A September 2026 publication examined biocatalytic cascades for synthesizing natural products with therapeutic potential. These examples show activity across commercial cosmetic ingredients and research on more selective routes to complex compounds.

The main approaches are recombinant proteins and peptides, precision fermentation, enzymatic synthesis and biocatalysis, plant cell culture, and phototrophic production. Recombinant methods make proteins in host cells; fermentation uses engineered microbes for target compounds; enzymes transform molecules directly. Plant cultures produce specialized metabolites, while phototrophic systems use light-driven organisms. Their trade-offs center on yield, product complexity, purification and scale-up.

The United States leads the country activity data with 1,780 documents, followed by Germany with 1,007 and China with 995. The United Kingdom and South Korea also have substantial recorded activity, with 667 and 627 documents respectively. These figures describe the country distribution in the dataset and do not by themselves measure commercial production or research quality.

Pharmaceuticals are the largest listed application, with 522 documents and 201 patents in the window. Cosmetics and personal care account for 242 documents, while agriculture and crop protection account for 175. Food and nutrition is a smaller but growing area in the measured period, with recent activity up 27.9%; cosmetic activity increased 10.4%.